Brainchip Holdings Ltd

BRN

BrainChip Holdings Ltd. engages in the development of software and hardware solutions for artificial intelligence and machine learning applications. The company is headquartered in Sydney, New South Wales and currently employs 66 full-time employees. The company went IPO on 2011-11-09. The principal activity of the Company is the development of software and hardware accelerated solutions for advanced artificial intelligence (AI) and machine learning applications with a primary focus on the development of its Neuromorphic Processor IP, Akida, to provide a complete ultra-low power and fast AI Edge network for vision, audio, olfactory and smart transducer applications. Its products include MetaTF, Akida1000 reference chip and Akida Enablement Platforms. The MetaTF development environment is a machine learning framework used for the creation, training, and testing of neural networks, supporting the development of systems for Edge AI on its Akida event domain neural processor. The Akida1000 reference chip is fully functional and enables working system evaluation. Its Akida Enablement Platforms include Akida PCIe Board, Akida Development Kit Shuttle PC and Akida Development Kit Raspberry Pi.

Brickworks Limited

BKW

Brickworks Ltd. engages in the manufacture and distribution of building products. The company is headquartered in Sydney, New South Wales and currently employs 2,193 full-time employees. The firm's Building Products Australia segment is engaged in the manufacturing of vitrified clay and concrete products used in the building industry. The major product lines in this segment include bricks, masonry blocks, pavers, roof tiles, floor tiles, fiber cement walling panels and roof battens. The Building Products North America segment is engaged in the manufacturing of vitrified clay and concrete products used in the building industry. The major product lines in this segment include bricks and masonry blocks. The Industrial Property segment is engaged in the utilization of opportunities associated with land owned by the Company, including the sale of property and investment in property trusts. The Investments segment holds investments in the Australian share market, both for dividend income and capital growth, and includes the investment in Washington H. Soul Pattinson and Company Limited and FBR Limited (FBR).

Hot Chili Limited

HCH

Hot Chili Ltd. engages in the identification, acquisition, exploration, evaluation, and development of mineral deposits. The company is headquartered in Perth, Western Australia. The company went IPO on 2010-05-03. The principal activity of the Company is engaged in mineral exploration. The firm is focused on copper exploration and development in Chile’s Atacama Region. The Company’s Costa Fuego Project is a copper mining hub in Region III on the Chilean coastal range. Its Chilean coastal range Costa Fuego Copper-Gold Project comprises the Cortadera, Productora and San Antonio deposits. The Cortadera deposit is focused on copper-gold discoveries in Chile. Productora is an advanced-stage copper-gold project. Its El Fuego copper Project encompasses two historic underground mines, which include San Antonio and Valentina. The Company’s wholly owned subsidiaries include Sociedad Minera El Corazon Limitada, Sociedad Minera Los Mantos SpA, Sociedad Minera Frontera SpA and Sociedad Minera Bandera SpA.

Mesoblast Limited

MSB

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. The company is headquartered in Melbourne, Victoria and currently employs 77 full-time employees. The company went IPO on 2004-12-16. The Company’s Remestemcel-L is mesenchymal lineage stromal cell product platform and is in late-stage development for treatment of systemic inflammatory diseases, including Pediatric steroid refractory acute Graft versus Host Disease (SR-aGVHD), acute respiratory distress syndrome (ARDS) and Biologic refractory inflammatory bowel disease. Its Rexlemestrocel-L is mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of advanced chronic heart failure (CHF) and chronic low back pain (CLBP) due to degenerative disc disease. Two products are commercialized in Japan and Europe by the Company’s licensees, and it has a commercial partnership in Europe and China for certain Phase III assets.

Paradigm Biopharmaceuticals Limited.

PAR

Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company engaged in researching and developing therapeutic products for human use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2015-08-19. The firm is focused on developing and commercializing pentosan polysulfate sodium (PPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, ageing, degenerative disease, infection, or genetic predisposition. PPS is a semi-synthetic drug manufactured from European beech xylans that are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs). Its multiple actions of PPS are mediated by targeting both NF-kB-dependent and NF-kB-independent pathways. The firm focuses on repurposing PPS for the treatment of Osteoarthritis (OA) and bone marrow lesions (BML), mucopolysaccharidosis (MPS), chronic heart failure (CHF) and alpha-viral arthritis (Ross River Virus and Chikungunya).